Abigail Brooks is an assistant editor for HCPLive. She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.
Clinical, Pathological Distinctions Provide Basis for Differentiating IgAN, IgAVN
February 7th 2024Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.
Read More
Home-Based Albuminuria Screening Cost-Effective for Preventing Kidney, Cardiovascular Events
February 6th 2024Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.
Read More
Hydroxychloroquine, Leflunomide Improve Proteinuria, Renal Function in IgAN
February 5th 2024Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.
Read More
Shared Decision-Making, Routine Monitoring Among Best Practices for Managing EoE
February 5th 2024The literature review discusses the rising incidence of eosinophilic esophagitis, highlighting the efficacy of proton pump inhibitors, challenges in diagnosis, and the need for collaborative decision-making in its management.
Read More
Hepatology Month in Review: January 2024
February 3rd 2024The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.
Read More
Long Time Coming: Pediatric Gastroenterologists React to New Dupilumab EoE Approval
February 1st 2024Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.
Read More
eGFR Based on Creatinine, Cystatin C May Offer Better CKD Threshold for Older Adults
January 31st 2024Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.
Read More